November 10, 2025 a 11:43 am
AMGN: Fundamental Ratio Analysis - Amgen Inc.
Amgen Inc. is a leading biotechnology company focusing on human therapeutics. With strong partnerships and products in various therapeutic areas, Amgen shows a stable outlook through its innovative drug portfolio. However, investors should consider market dynamics since the sector remains competitive.
Fundamentals Rating
Amgen holds a solid B+ fundamental rating with competitive scores indicating a healthy financial standing. Below are the assessment categories and associated scores:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
The historical performance indicates consistent scores. Below are the scores from previous and current evaluations:
| Date | Overall | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-07 | 3 | 5 | 5 | 5 | 1 | 2 | 1 |
| N/A | 0 | 5 | 5 | 5 | 1 | 2 | 1 |
Analyst Price Targets
Analyst projections suggest stability with a range from low to high estimates. Below are the current estimates:
| High | Low | Median | Consensus |
|---|---|---|---|
| $342 | $300 | $315 | $319 |
Analyst Sentiment
Analyst sentiment is favorable, predominantly suggesting 'Buy'. Here’s the breakdown:
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 22 | |
| Hold | 11 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Amgen Inc. displays robust fundamentals with a positive outlook in the biotechnology sector. Despite its high debt-to-equity ratio, its strong revenue from various products points to growth potential. Analysts show a predominant 'Buy' consensus, reflecting confidence in the stock's future performance. However, investors should remain aware of industry competition and other market dynamics while considering this stock.